By the Top Tier Newswire AI Desk · October 15, 2026 at 12:01 AM ET · reviewed against 36 wire stories
LIQUIDIA CORP (LQDA) is up +26.59% in the latest session. Our newswire has captured 36 stories on LQDA across 16 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Liquidia Corp (LQDA) shares surged 26.59% to close at $33.94, driven by a settlement with United Therapeutics that resolved long-standing patent litigation. The agreement removes a major legal obstacle surrounding the company’s lead product, Yutrepia, which had previously caused significant volatility in the stock price.
What Happened
Liquidia and United Therapeutics reached a settlement that concludes their patent dispute, a development that analysts view as a positive catalyst for the company’s future. BTIG upgraded the stock, describing the settlement as better than the best-case scenario. LifeSci Capital noted that the agreement removes a major obstacle that could have discouraged potential buyers from pursuing an acquisition. The settlement follows a federal judge’s ruling in September that had previously impacted the stock’s valuation. Wells Fargo maintains an Equal-Weight rating on the shares and raised its price target to $33.
What The Data Shows
The stock’s market capitalization stands at $2.5 billion with a P/E ratio of 18.1. Trailing twelve-month revenue increased by 2233.6%, and the company reported a net margin of 30.7%. The 52-week range spans from $21.94 to $93.61. Over the last eight sessions, the stock moved up 22.9% from $27.48 to $33.78. Unusual options activity included three notable prints with $4.9 million in call premium and no put premium, with the largest single print at $2.7 million. Insider filings show 19 sells totaling $49.9 million over the last 90 days, with no buys recorded. Recent sales were executed by Chief Accounting Officer Dana Boyle, Chief Business Officer Jason Adair, and Chief Development Officer Sanjeev Khindri on October 12, 2026. Congressional disclosures indicate three sales by Donald J. Trump in the last 90 days, with the most recent filing on October 8, 2026.
What To Watch
Investors will monitor the stock’s reaction to the settlement and any subsequent analyst adjustments. The coverage breadth includes 36 stories from 16 sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 36 stories · 60/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
7h agoYahoo FinanceBEARISH 42General
How Much Downside Is Left In Liquidia Stock?
Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%. Reuters reported that the stock dropped nearly 50% on September 30 after a federal judge ruled that Yutrepia, Liquidia's inhaled lung drug, infringes a United Therapeutics patent. Liquidia subsequently settled all pending litigation with United Therapeutics on October 13, stating that Yutrepia will remain available to patients with PAH without disruption. If the wider market sells off from here, how mu
12h agoBarchartBULLISH 74General
What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring
Liquidia stock rallies on a settlement with United Therapeutics. But is it already too late to invest in LQDA shares?
12h agoSeeking AlphaBULLISH 64General
Liquidia soars 27% after settlement resolves litigation
Liquidia (LQDA) surges after settling United Therapeutics litigation, lifting uncertainty around YUTREPIA.
16h agoThe FlyBULLISH 74General
Liquidia rises 25.3%
17h ago24/7 Wall St.BULLISH 58General
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank. Whether that price was a bargain or a slow bleed depends on one number Liquidia has not yet revealed.
18h agoBusiness InsiderBULLISH 64Analyst
Liquidia adds over 30% on United Thera. settlement; BTIG upgrades
Liquidia (LQDA) stock surges as the company settles all lawsuits with United Therapeutics (UTHR), prompting BTIG to upgrade the firm. Read more here.
18h agoMarketChameleonBULLISH 58General
Liquidia Rallies to $34.05 as Investor Probe Revives Focus on the Yutrepia Patent Setback
October 14, 2026
Liquidia (LQDA) traded at $34.05 as of 10:26 AM, rising sharply during market hours as a law firm press release renewed attention on an investor investigation tied to prior patent-litigation fallout. The notice references a Sept. 30, 2026 court ruling finding Yutrepia infringed two claims of United Therapeutics’ ’327 patent and notes no lawsuit has been filed as the investigation continues.
18h agoStocktwits NewsBULLISH 78General
LQDA Stock Rockets 40% Today – BTIG Calls United Therapeutics Settlement ‘Better Than Best-Case Scenario’
LifeSci Capital said the agreement removes a major obstacle that could have discouraged potential buyers from pursuing an acquisition of Liquidia.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →